Matches in SemOpenAlex for { <https://semopenalex.org/work/W2063278839> ?p ?o ?g. }
- W2063278839 endingPage "2176" @default.
- W2063278839 startingPage "2164" @default.
- W2063278839 abstract "Selective serotonin reuptake inhibitors (SSRIs) and other antidepressants are often prescribed to amyotrophic lateral sclerosis (ALS) patients; however, the impact of these prescriptions on ALS disease progression has not been systematically tested. To determine whether SSRIs impact disease progression, fluoxetine (Prozac, 5 or 10 mg/kg) was administered to mutant superoxide dismutase 1 (SOD1) mice during one of three age ranges: neonatal [postnatal day (P)5-11], adult presymptomatic (P30 to end stage), and adult symptomatic (P70 to end stage). Long-term adult fluoxetine treatment (started at either P30 or P70 and continuing until end stage) had no significant effect on disease progression. In contrast, neonatal fluoxetine treatment (P5-11) had two effects. First, all animals (mutant SOD1(G93A) and control: nontransgenic and SOD1(WT)) receiving the highest dose (10 mg/kg) had a sustained decrease in weight from P30 onward. Second, the high-dose SOD1(G93A) mice reached end stage ∼8 days (∼6% decrease in life span) sooner than vehicle and low-dose animals because of an increased rate of motor impairment. Fluoxetine increases synaptic serotonin (5-HT) levels, which is known to increase spinal motoneuron excitability. We confirmed that 5-HT increases spinal motoneuron excitability during this neonatal time period and therefore hypothesized that antagonizing 5-HT receptors during the same time period would improve disease outcome. However, cyproheptadine (1 or 5 mg/kg), a 5-HT receptor antagonist, had no effect on disease progression. These results show that a brief period of antidepressant treatment during a critical time window (the transition from neonatal to juvenile states) can be detrimental in ALS mouse models." @default.
- W2063278839 created "2016-06-24" @default.
- W2063278839 creator A5050915751 @default.
- W2063278839 creator A5061671378 @default.
- W2063278839 creator A5061935544 @default.
- W2063278839 creator A5063753709 @default.
- W2063278839 creator A5069039017 @default.
- W2063278839 creator A5079411871 @default.
- W2063278839 creator A5079771790 @default.
- W2063278839 creator A5089717747 @default.
- W2063278839 date "2014-06-01" @default.
- W2063278839 modified "2023-10-01" @default.
- W2063278839 title "Effect of fluoxetine on disease progression in a mouse model of ALS" @default.
- W2063278839 cites W1508010432 @default.
- W2063278839 cites W1538003228 @default.
- W2063278839 cites W1554056672 @default.
- W2063278839 cites W1558688164 @default.
- W2063278839 cites W1607372012 @default.
- W2063278839 cites W194990313 @default.
- W2063278839 cites W1966860196 @default.
- W2063278839 cites W1967379094 @default.
- W2063278839 cites W1967640887 @default.
- W2063278839 cites W1968533747 @default.
- W2063278839 cites W1971941573 @default.
- W2063278839 cites W1976114760 @default.
- W2063278839 cites W1980708963 @default.
- W2063278839 cites W1981151802 @default.
- W2063278839 cites W1981668949 @default.
- W2063278839 cites W1982360670 @default.
- W2063278839 cites W1986300410 @default.
- W2063278839 cites W1986453870 @default.
- W2063278839 cites W1986740990 @default.
- W2063278839 cites W1986878360 @default.
- W2063278839 cites W1987359977 @default.
- W2063278839 cites W1992558019 @default.
- W2063278839 cites W1994637967 @default.
- W2063278839 cites W1995185770 @default.
- W2063278839 cites W1995283839 @default.
- W2063278839 cites W1996567054 @default.
- W2063278839 cites W1996576454 @default.
- W2063278839 cites W1996958452 @default.
- W2063278839 cites W1997158323 @default.
- W2063278839 cites W1998357797 @default.
- W2063278839 cites W1999967173 @default.
- W2063278839 cites W2001842574 @default.
- W2063278839 cites W2002410482 @default.
- W2063278839 cites W2002515362 @default.
- W2063278839 cites W2003572520 @default.
- W2063278839 cites W2005914706 @default.
- W2063278839 cites W2005972539 @default.
- W2063278839 cites W2009578847 @default.
- W2063278839 cites W2011816953 @default.
- W2063278839 cites W2014935008 @default.
- W2063278839 cites W2016675176 @default.
- W2063278839 cites W2021200129 @default.
- W2063278839 cites W2027681941 @default.
- W2063278839 cites W2027886291 @default.
- W2063278839 cites W2029465838 @default.
- W2063278839 cites W2030246436 @default.
- W2063278839 cites W2031280190 @default.
- W2063278839 cites W2033021683 @default.
- W2063278839 cites W2033027472 @default.
- W2063278839 cites W2034396455 @default.
- W2063278839 cites W2040615884 @default.
- W2063278839 cites W2042173519 @default.
- W2063278839 cites W2043112113 @default.
- W2063278839 cites W2045221789 @default.
- W2063278839 cites W2045461325 @default.
- W2063278839 cites W2046433440 @default.
- W2063278839 cites W2047867249 @default.
- W2063278839 cites W2053109408 @default.
- W2063278839 cites W2053375881 @default.
- W2063278839 cites W2053702145 @default.
- W2063278839 cites W2057060520 @default.
- W2063278839 cites W2057566553 @default.
- W2063278839 cites W2058313056 @default.
- W2063278839 cites W2067591875 @default.
- W2063278839 cites W2068065195 @default.
- W2063278839 cites W2068614245 @default.
- W2063278839 cites W2070720564 @default.
- W2063278839 cites W2075620663 @default.
- W2063278839 cites W2078442444 @default.
- W2063278839 cites W2080044980 @default.
- W2063278839 cites W2080922861 @default.
- W2063278839 cites W2085204538 @default.
- W2063278839 cites W2086246680 @default.
- W2063278839 cites W2087402265 @default.
- W2063278839 cites W2088047679 @default.
- W2063278839 cites W2088083180 @default.
- W2063278839 cites W2092756373 @default.
- W2063278839 cites W2093173553 @default.
- W2063278839 cites W2094288912 @default.
- W2063278839 cites W2096386031 @default.
- W2063278839 cites W2107065376 @default.
- W2063278839 cites W2107768418 @default.
- W2063278839 cites W2108568993 @default.
- W2063278839 cites W2112525241 @default.
- W2063278839 cites W2113390309 @default.